Testing a new medication to help people with severe chronic lung disease

Plain-English translation of NCT06959095 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see if it can help people with moderate-to-severe COPD (a chronic lung disease that makes breathing difficult) who are already on standard inhalers but still struggling. The study will compare plus standard care to a placebo (a dummy pill) plus standard care in nearly 1,000 adults. Researchers want to know if this medication can reduce flare-ups and improve quality of life for people whose lung disease is not well controlled.

Many people with COPD continue to have frequent, serious flare-ups even when taking the best available inhaler treatments. This medication targets a specific type of inflammation in the lungs, and this trial will test whether it can help patients who need better control of their disease.

Do you qualify?

You likely qualify if…

you are between 40 and 80 years old
you have been diagnosed with moderate-to-severe COPD for at least one year, with a history of at least 2 moderate or 1 severe flare-up in the past 12 months
you have elevated eosinophils (a type of white blood cell) in your blood
you have a significant smoking history (at least 10 pack-years of cigarettes)
you have been on a combination inhaler therapy (inhaled corticosteroid plus two other types of inhalers) for at least 6 months

You likely don't qualify if…

you have been diagnosed with asthma
you have had pneumonia, a COPD flare-up, or a lower respiratory infection in the past 4 weeks
you require oxygen supplementation for more than 12 hours per day
you have severe heart problems, including right heart failure or severe pulmonary high blood pressure
you have a known parasitic infection within the past 6 months

What participation looks like

If you qualify and enroll, you will be randomly assigned to receive either the new medication or a placebo, both given alongside your regular inhaler treatments. You will continue taking your standard COPD medications throughout the trial. You will visit the study center multiple times for check-ups, breathing tests, and blood work to help researchers track how the medication affects your lung function, flare-up rates, and overall symptoms.

AI-generated summary from trial data · Jun 5, 2026 · Not medical advice

Trial locations(15 sites)

United States

GSK Investigational Site, Loxahatchee Groves, Florida

GSK Investigational Site, Miami, Florida

GSK Investigational Site, Rock Hill, South Carolina

GSK Investigational Site, Corsicana, Texas

China

GSK Investigational Site, Changsha, Hunan